Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase
about
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)Identification of NAD(P)H Quinone Oxidoreductase Activity in Azoreductases from P. aeruginosa: Azoreductases and NAD(P)H Quinone Oxidoreductases Belong to the Same FMN-Dependent Superfamily of EnzymesStructural and biochemical characterization of MdaB from cariogenic Streptococcus mutans reveals an NADPH-specific quinone oxidoreductaseNQO2 gene is associated with clozapine-induced agranulocytosisCrystal structure of quinone reductase 2 in complex with resveratrolNQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levelsHeterologous expression of xenobiotic mammalian-metabolizing enzymes in mutagenicity tester bacteria: an update and practical considerations.Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors.NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomasHuman carbonyl reduction pathways and a strategy for their study in vitro.Quinone reductases multitasking in the metabolic world.PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.Fortilin potentiates the peroxidase activity of Peroxiredoxin-1 and protects against alcohol-induced liver damage in mice.Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factorA unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin CResveratrol: Biological and pharmaceutical properties as anticancer molecule.Quinone reductase 2 is a catechol quinone reductaseDissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinonesMitochondrial diaphorases as NAD⁺ donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition.Imatinib and spironolactone suppress hepcidin expression.Azoreductases in drug metabolism.Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.The antidote effect of quinone oxidoreductase 2 inhibitor against paraquat-induced toxicity in vitro and in vivo.Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.Expression of NAD(P)H:quinone oxidoreductase 1 in HeLa cells: role of hydrogen peroxide and growth phase.Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity.Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors.Functional role of Trp-105 of Enterococcus faecalis azoreductase (AzoA) as resolved by structural and mutational analysis.Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.Structures of AzrA and of AzrC complexed with substrate or inhibitor: insight into substrate specificity and catalytic mechanism.NQO2:FAD dimer reduces quinones to hydroquinonesThe ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2).Identification of KPNB1 as a Cellular Target of Aminothiazole Derivatives with Anticancer Activity.Targeting enzymes to cancers--new developments.
P2860
Q27653890-9F71F2C2-E701-4D17-9B5D-93C84BF2CD02Q27684286-A73C258F-2D35-4057-AD02-6FFB79029D73Q27689717-184F8C88-BF3A-4104-9FC9-5834D096AF51Q28184506-987E5EE4-27B2-4C7E-B21E-97DB2AF9F772Q28280502-DEFFD68F-0863-4845-8A5B-58C86497BAE3Q28741474-B7F6A58D-0BAB-47F6-B23E-A3175E9C7974Q33942241-763216A8-0D83-46EC-80B1-E05C5E382D3FQ34146957-81FA8C0F-499F-43D8-B824-AA89A7972375Q35055410-69474C2A-CA33-456D-BB79-45109F1ACAE7Q35828036-D2811D62-2ABA-49C1-89DA-81E3BA612E2BQ35956182-ECC91B02-4B57-4159-8592-C17E9E0274B8Q36393755-2F5EBBDB-220A-4A23-9669-345CE1AFA650Q36423249-5A7E558D-CCDC-4735-B96F-771E3E242B48Q36611873-B771D006-8113-4B5E-AB42-DEEF099F7D7BQ36641702-78E7A6ED-AF41-4D40-B322-ED23F25EB5E7Q36848141-EF1F125D-EE76-408E-A3BF-BC2EE12687D2Q36856168-20F8EBFE-2378-4DB7-BAAC-B79B3472A4A9Q37033761-BCB67D0A-B745-4A13-8233-040B8F37F758Q37352680-69F166E5-65F0-41E9-881D-3DF11A7BCE7DQ37657133-4B2C87E9-3700-4992-94DC-948769BC22ACQ38708587-285666C5-DAE0-4DC8-AF31-DCB1B5114E53Q38917152-F3E36644-8C29-4BB3-8B54-1F597B5690D9Q39515397-1F6B7D4F-BE2C-4D0F-99F5-57E41A772312Q39587113-156E4883-A9DB-4855-A931-B0709EF796EFQ40296515-46F1580B-82BD-4EDE-B0C4-00ECAC3E8421Q40516906-0A4B7013-E44D-4984-9FCA-FD1F67F41AF2Q42253314-7B56A531-0D78-4EAB-9C06-5EF7A66A3AFCQ42421190-BCD6B168-C19C-48ED-B610-8FACDD921659Q43236564-CC25FA45-38A1-400E-A3EE-9EA24601B582Q43744817-8447427B-7B71-4D43-8980-8AAA48A9E46EQ44156025-01A40FA1-5FC0-4F63-B902-7FC74A92A6DFQ44760560-7F8DBD3B-E1E8-4440-BD43-CD2663505155Q46239461-A1F937AD-F775-4814-AF6B-847ABC29E475Q46402017-6D6F9912-263B-4D2E-9D92-FF500857FB38Q47251583-32AB9F5A-16EB-46F2-BFB4-264785ABBD74Q50225328-AC4BBF4E-B5D1-4103-BF15-15B85EB4691DQ50295344-03073F0E-DD2D-44D1-9A1F-F88722411323Q50770722-7B79F132-400A-4C41-8629-993F8FF94D95Q51729791-74158FC9-8681-4D7E-918E-184124412745Q53619323-8A9FC0F0-95B4-4BCF-A9DD-26FA07A2998A
P2860
Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@ast
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@en
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@nl
type
label
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@ast
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@en
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@nl
prefLabel
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@ast
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@en
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@nl
P2093
P356
P1476
Catalytic properties of NAD(P) ...... oside dependent oxidoreductase
@en
P2093
A K Jaiswal
P356
10.1006/ABBI.1997.0344
P407
P577
1997-11-15T00:00:00Z